Key facts
- This page summarizes Gurdev Dave Singh's Form 4 filing for Vivos Therapeutics, Inc. (VVOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2021, 21:44.
Gurdev Dave Singh - 05 Aug 2021 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)
- Reporting relationship
- Chief Medical Officer, Director, 10%+ Owner
- Issuer ticker
- VVOS
- Reported as of
- 05 Aug 2021
- Net transaction value
- +$81,600
- Reporting owner signature
- /s/ Brad Amman as attorney-in-fact for G.Dave Singh
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Gurdev Dave Singh filed Form 4 for Vivos Therapeutics, Inc. (VVOS) on 10 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$81,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VVOS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,219,705
- Date
- 05 Aug 2021
- Ownership
- See footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VVOS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $81,600
- Shares
- +30,000
- Change %
- +180%
- Price
- $2.72*
- Shares after
- 46,667
- Date
- 05 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,667
- Exercise price
- $2.72
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares held by Himmat LP, of which reporting person is a member and manager.
Footnote F2
30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.